肝細胞癌治療後の再発抑制補助療法（インターフェロン療法，動注療法，免疫細胞療法）

概要

論文の詳細を見る
The underlying hepatopath may cause intra-hepatic recurrence even if curative resection for hepatocellular carcinoma (HCC) is achieved. Two patterns of intra-hepatic recurrence is exist, multicentric carcinogenesis with chronic hepatopath and intra-hepatic metastasis. We must diagnose the difference of these 2 characters after treatment, hepatectomy or ablation, for HCC and perform the post-operative adjuvant therapy expecting the 2 patterns. The prevention of multicentric carcinogenesis is postoperative interferon (IFN) therapy on hepatitis C virus-related HCC and the prevention of intrahepatic metastasis is postoperateive transcatheter arterial infusion chemotherapy (TAI) and cell immunotherapy on advanced HCC. The postoperative adjuvant therapy for HCC was found to be an effective adjuvant therapy that significantly improved survival and disease-free survival rates, and we have been not satisfied with the therapiatic effects. Although randomized controlled study with a greater number of patients is necessary.
特定非営利活動法人 Microwave Surgery研究会の論文